Category: Stent WarsSyndicate content

ACC 2014 Roundup: Study shows long-term benefits for some CRT-D patients

March 31, 2014 by Brad Perriello

Seven-year results from Boston Scientific's MADIT-CRT trial show long-term benefits for some patients with mild heart failure.

ACC 2014 Roundup: Study shows long-term benefits for some CRT-D patients

Some patients with mild heart failure show significant, long-term benefits from cardiac-resynchronization therapy, according to the 7-year results from Boston Scientific's (NYSE:BSX) MADIT-CRT clinical trial presented at the American College of Cardiology's annual meeting over the weekend.

Get the complete picture with a MassDevice Plus membership. Registered users can login here.

Stent wars: Shrinkage concerns resurface in Medtronic/Boston Scientific DES trial

February 3, 2014 by Arezu Sarvestani

Medtech titan Medtronic touts a relatively minor clinical trial win for the physical integrity of its Resolute drug-eluting stent in what is otherwise a tie with Boston Scientific's Promus Element device.

Stent wars: Medtronic's Resolute DES bests Boston Scientific's Promus Element for stent deformation

Get the complete picture with a MassDevice Plus membership. Registered users can login here.

Supreme Court denies stent pioneer Saffran in $600M patent case against J&J's Cordis

January 28, 2014 by Brad Perriello

The U.S. Supreme Court denies stent pioneer Dr. Bruce Saffran's appeal of a $600 million patent infringement decision to Johnson & Johnson's Cordis stent-making arm.

YYmeta

Johnson & Johnson's (NYSE:JNJ) Cordis stent-making arm won the final round in a patent infringement battle with stent pioneer Dr. Bruce Saffran when the U.S. Supreme Court yesterday declined to hear Saffran's appeal.

Get the complete picture with a MassDevice Plus membership. Registered users can login here.

Boston Scientific wins FDA approval for Promus Premier stent

November 25, 2013 by Brad Perriello

The FDA grants pre-market approval to Boston Scientific's next-generation Promus Premier coronary stent.

Boston Scientific wins FDA approval for Promus Premier stent

Boston Scientific (NYSE:BSX) said the FDA granted pre-market approval for its next-generation coronary stent, the Promus Premier.

Natick, Mass.-based Boston Scientific said it plans an immediate release for the Promus Premier, a drug-eluting stent made of a platinum-chromium alloy coated with everolimus.

Get the complete picture with a MassDevice Plus membership. Registered users can login here.

Federal Circuit denies re-hearing for Cordis patent claims against Medtronic, Abbott, Boston Scientific

October 15, 2013 by Brad Perriello

The U.S. Court of Appeals for the Federal Circuit declines to revisit its decision to uphold a lower court's decision to invalidate patents for drug-eluting coronary stent technology.

Federal Circuit denies re-hearing for Cordis patent claims against Medtronic, Abbott, Boston Scientific

A federal appeals court last week declined to revisit its decision to uphold the invalidation of patents covering drug-eluting stent technology.

Get the complete picture with a MassDevice Plus membership. Registered users can login here.

Boston Scientific settles stent patent spat with OrbusNeich

September 17, 2013 by Brad Perriello

Boston Scientific agrees to pay an undisclosed amount to settle patent infringement cases against OrbusNeich in the U.S. and Europe over coronary stent technology.

Boston Scientific settles stent patent spat with Orbusneich

Boston Scientific (NYSE:BSX) agreed to pay an undisclosed amount to put its long-running patent war with OrbusNeich Medical to rest.

Get the complete picture with a MassDevice Plus membership. Registered users can login here.

Boston Scientific closes enrollment in Synergy stent trial

September 13, 2013 by Brad Perriello

Boston Scientific finishes enrolls the last of 1,684 patients in the Evolve II trial of its Synergy drug-eluting stent.

Boston Scientific closes enrollment in Synergy stent trial

Boston Scientific (NYSE:BSX) said it finished enrolling 1,684 patients in a clinical trial of its next-generation Synergy drug-eluting stent, aiming to use the data to back regulatory nods in the U.S. and Canada.

Get the complete picture with a MassDevice Plus membership. Registered users can login here.

Built on an AdaptiveTheme using Drupal by Michael Knapp  mknapp